Cancer drug developer Arcus Biosciences' Q3 net loss widens

Arcus Biosciences

28/10/2025 20:21

Overview

Arcus Q3 revenue declined, but beat analyst expectations

Net loss for Q3 increased to $135 mln from $92 mln last year

Company maintains $841 mln in cash, supporting pipeline development

Outlook

Arcus expects 2025 full-year revenue between $225 mln and $235 mln

Company anticipates multiple data readouts from ARC-20 study in 2026

Result Drivers

CASDATIFAN PERFORMANCE - Casdatifan demonstrated 12.2 months median progression-free survival in late-line kidney cancer patients, highlighting its potential as a best-in-class therapy

TAIHO PARTNERSHIP - Taiho exercised its option for an exclusive license to casdatifan in Japan and certain territories in Asia, providing Arcus with option and milestone payments

R&D EXPENSES - Increased R&D expenses were driven by costs for late-stage programs, including PRISM-1 and PEAK-1, partially offset by lower costs from STAR-221

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$26 mln
$24.60 mln (10 Analysts)
Q3 Net Income
-$135 mln
Q3 Operating Expenses
$168 mln
Q3 Operating Income
-$142 mln
Q3 Pretax Profit
-$135 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Arcus Biosciences Inc is $29.00, about 35.9% above its October 27 closing price of $18.60

Press Release: ID:nBw8rHNdba

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)